Ascentage Pharma's Upcoming Appearances at Investor Conferences
ROCKVILLE, Md. and SUZHOU, China - Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global leader in biopharmaceutical development, is ready to engage with investors by participating in three key conferences in December. This comes as part of the company's strategy to enhance visibility and foster relationships within the healthcare investment community.
Conference Schedule
The following conferences are on the horizon for Ascentage Pharma's management:
- Piper Sandler 37th Annual Healthcare Conference: A fireside chat set for 9:00 am EST on December 2.
- Evercore ISI HealthCONx Conference: Another fireside chat scheduled for 3:50 pm EST on December 3.
- Citi 2025 Global Healthcare Conference: One-on-one meetings will take place on December 4.
About Ascentage Pharma Group International
Ascentage Pharma is renowned for its focus on addressing unmet medical needs in oncology. The company is committed to the discovery, development, and commercialization of innovative therapies designed to transform cancer treatment landscapes. Their impressive pipeline features groundbreaking drug candidates, prominently including inhibitors targeting critical apoptotic pathways like Bcl-2 and MDM2-p53, as well as advanced kinase inhibitors.
Innovative Products and Clinical Trials
The flagship product of Ascentage Pharma is Olverembatinib, the first approved third-generation BCR-ABL1 inhibitor in China. This drug is pivotal for treating patients with chronic myeloid leukemia (CML) who exhibit T315I mutations. With significant acceptance, all indications are listed on the China National Reimbursement Drug List (NRDL). Currently, the company is conducting a global Phase III trial named POLARIS-2 to evaluate Olverembatinib for CML, along with additional trials aimed at newly diagnosed Ph+ acute lymphoblastic leukemia (ALL) patients and those with succinate dehydrogenase-deficient gastrointestinal stromal tumors (GIST).
Moreover, Lisaftoclax, Ascentage's second approved product, showcases their commitment to enhancing treatment options for hematologic malignancies. Following its approval in China, Lisaftoclax is set to make significant strides in treating chronic lymphocytic leukemia/small lymphocytic lymphoma for patients previously treated with systemic therapies, such as Bruton’s tyrosine kinase inhibitors. The company is currently running four global Phase III trials focused on diverse patient demographics and conditions.
Strategic Collaborations and Future Goals
Ascentage Pharma's robust research and development capabilities have established influential partnerships worldwide. Collaborations with leading biotech and pharmaceutical firms, including Takeda, AstraZeneca, Merck, and Pfizer, as well as esteemed research institutions such as the Dana-Farber Cancer Institute and Mayo Clinic, reinforce their position in the industry. These alliances are crucial for advancing innovative cancer therapies and enhancing patient outcomes globally.
Looking Ahead
As Ascentage Pharma prepares for these conferences, it emphasizes its ongoing commitment to innovation and collaboration in the biopharmaceutical field. With a strong portfolio of products and partnerships, the future looks promising for the company as it aims to expand its impact on cancer care.
Frequently Asked Questions
What is Ascentage Pharma's main focus?
Ascentage Pharma primarily focuses on developing novel therapies to address unmet medical needs in cancer.
Where will Ascentage Pharma be presenting in December?
Ascentage Pharma will present at the Piper Sandler Healthcare Conference, Evercore ISI HealthCONx Conference, and Citi Global Healthcare Conference.
What are some of the company's notable products?
Notable products include Olverembatinib, a third-generation BCR-ABL1 inhibitor, and Lisaftoclax, a novel Bcl-2 inhibitor for hematologic malignancies.
Who are some of Ascentage Pharma's partners?
The company collaborates with various top-tier biotechnology and pharmaceutical firms, including Takeda, AstraZeneca, and Merck.
What qualifications back Ascentage Pharma's research?
The company has strong R&D capabilities supported by its partnerships with renowned research institutions, ensuring high standards of innovation and efficacy.
